Recent notifications from Cases of Nipah virus infection in the Indian state of West Bengal They have brought this highly lethal zoonotic pathogen back to the forefront of the news. Although the infections have occurred thousands of kilometers from Europe, the temporal proximity to the Covid-19 pandemic has reignited logical questions: what exactly is happening in India and what real implications does it have for Spain and the rest of the European continent?
International health authorities insist that, with the information available, The current situation does not justify widespread alarm.India has officially confirmed two cases in healthcare workers, and the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) consider the risk to Europe to be low. Even so, Nipah virus remains a concern due to its high mortality rate, its animal origin, and the lack of authorized vaccines.
Nipah virus situation in India: what is known about the latest outbreak
In January 2026, India's Minister of Health announced Two confirmed cases of Nipah virus disease in West BengalBoth patients are healthcare professionals —a young man and woman— who work at a private hospital in Barasat, about 25 kilometers from the center of Calcutta, a densely populated megacity with abundant international connections.
The possibility of a virus of this type spreading from rural or semi-urban environments to a metropolitan area with worldwide flights is, logically, a cause for concern and close monitoring. However, Official data points to a very localized and strictly controlled outbreakThe WHO has reiterated that, as of January 30, 2026, only these two cases have been confirmed and no new associated infections have been identified.
Indian authorities have conducted an intensive search. 196 close contacts have been identified, monitored and analyzed linked to the two healthcare workers. All of them remain asymptomatic and have tested negative in specific virus detection tests. This result supports the idea that, for the moment, there is no evidence of community transmission in the area.
The Indian government has emphasized that A national health alert has not been declaredHowever, the situation remains under continuous monitoring and standard public health measures have been implemented: contact tracing, enhanced biosecurity in the health centers involved, and isolation protocols for suspected cases.
India is no stranger to Nipah: Since 2001, at least eight outbreaks have been recorded.Three in West Bengal and five in the southern state of Kerala. Even so, most have been localized events that were contained using relatively conventional public health strategies.
Risk assessment for Europe and Spain
In light of the new development in India, the European Centre for Disease Prevention and Control (ECDC)The Stockholm-based organization has conducted a specific evaluation. Its conclusion is clear: The risk to the European population is considered very low, both in terms of the probability of importing cases and the potential for subsequent transmission within the continent.
The ECDC notes that the two confirmed cases are workers from the same hospital who had contact with each other at the end of December 2025. The link to a single healthcare setting and the absence of documented secondary infections suggest a outbreak confined to the hospital setting, with no indication of widespread circulation in the community.
One of the factors that carries the most weight in the European assessment is the ecology of the virus. The natural reservoir of Nipah is the fruit bats of the genus Pteropus, also known as flying foxes, species that are not present in Europe. This means that, even if a single imported case were to arrive, The virus's ability to establish itself and spread sustainably on the continent would be very limited..
Although it cannot be 100% ruled out that an infected traveler from India or Bangladesh could arrive in Spain or another European country, experts emphasize that this type of scenario would be exceptional and, in principle, manageable with the tools available: early detection, isolation, and protective measures in the healthcare environment. Nipah transmission requires close contact and does not spread efficiently over long distances., making it difficult for it to become a problem comparable to the SARS-CoV-2 coronavirus.
Meanwhile, countries in the Asian region such as Thailand, Nepal, and Cambodia have strengthened surveillance and controls on travelers from India.These additional barriers are part of routine actions against emerging infectious threats. They also indirectly contribute to reducing the likelihood of the virus spreading to other continents.
Recommendations for European travelers to India and South Asia
For Spanish and European citizens planning to travel to West Bengal or other areas where previous outbreaks have been identified, the recommendations are prudent but simple. The ECDC and WHO emphasize that, with basic preventative measures, the individual risk of infection is very low.
General precautionary guidelines include avoiding unnecessary contact with domestic or wild animals —particularly pigs and bats— and their fluids. Do not consume food that may have been exposed to fruit bats. Another key indicator is: partially bitten or damaged fruit, or produce picked outdoors at night, are examples to discard.
A well-documented route of transmission in Bangladesh and West Bengal is through raw date palm sap, known locally as khejur-er roshThis juice, consumed raw during the winter months, can become contaminated with the saliva, urine, or feces of bats that come to lick the sap at night. Therefore, it is recommended Avoid consuming raw sap and similar unpasteurized products when traveling to areas where outbreaks have been recorded.
The usual food hygiene measures —Wash, peel, and cook fruits and vegetables thoroughly.Taking precautions—including consuming safe water and beverages—is especially important in contexts where zoonotic pathogens are present. Additionally, it is advisable to reduce exposure to areas where large bat colonies roost and to follow local biosafety guidelines.
If you experience compatible symptoms during or after a trip—high fever, severe malaise, respiratory problems, or neurological disorders—it is advisable consult with health services as soon as possibleindicating the places visited and any potential exposure to animals or foods that may pose a risk. Detailed travel information facilitates differential diagnosis and the early implementation of necessary measures.
What is the Nipah virus and how did it emerge
The Nipah virus (NiV) is a emerging zoonotic pathogen belonging to the genus Henipavirus It belongs to the Paramyxoviridae family. It is a single-stranded RNA virus with negative polarity, which means it has a high capacity for mutation and adaptation to new hosts, as is the case with other RNA viruses involved in numerous emerging infectious diseases.
The first descriptions of human infection by Nipah date back to the outbreak that affected pig farmers in Malaysia and Singapore between 1998 and 1999The virus's name comes from Sungai Nipah, a Malaysian town where some of the workers who developed severe encephalitis lived. That outbreak resulted in nearly 300 cases and more than 100 deaths, and forced the culling of over a million pigs to break the chain of transmission, with a significant economic impact.
Since then, they have been documented recurring outbreaks in South Asia, especially in Bangladesh and certain regions of northeastern India, such as West Bengal. In Bangladesh, outbreaks have been observed almost every year since 2001, generally in rural or semi-rural areas with close interaction between people, bats, and domestic animals. Infections have also been reported in the Philippines, attributed to Nipah or very closely related viruses.
To date, the following have been recorded worldwide: at least 750-760 human cases of Nipah infectionwith around 430-440 deaths. The case fatality rate varies considerably between outbreaks, but it typically ranges from 40% to 75%, making it an extremely serious pathogen. Furthermore, approximately a quarter of survivors suffer long-term neurological sequelae, such as persistent seizures or personality changes.
Because of these characteristics, the WHO classifies Nipah as high-risk pathogen and research priority, within its Research and Development (R&D Blueprint) initiative, which identifies the agents with the greatest epidemic potential for which there are no adequate medical countermeasures.
Symptoms and progression of the disease
Nipah virus infection usually presents with nonspecific initial phase, similar to a severe fluThis makes early detection difficult if the epidemiological context is not taken into account. The incubation period usually ranges from four to 21 days, although longer intervals have been described in exceptional cases.
The first signs include fever, headache, myalgia (muscle pain), intense tiredness, vomiting, and general malaise. Some patients develop respiratory symptoms such as cough, difficulty breathing or pneumonia; the severity of this condition varies depending on the outbreak and the patient's condition.
The most feared complication is the Encephalitis, an inflammation of the brain which may appear days or weeks after the onset of general symptoms. It manifests with confusion, drowsiness, altered level of consciousness, seizures, and even coma. In some cases, associated meningitis has also been described.
The combination of respiratory failure and neurological damage explains the virus's high mortality rate. Those who survive may suffer long-lasting neurological sequelaeThese symptoms include cognitive problems, chronic seizures, or behavioral changes. In addition, episodes of late-onset encephalitis, with relapses or reactivation of the virus months or years after the initial infection, have been described, although these are rare.
At the other end of the clinical spectrum, there are also asymptomatic or very mild infections These cases can go undetected, complicating the accurate estimation of the total number of infections. Despite this, the high fatality rate among detected cases leads authorities to consider Nipah a serious threat requiring constant monitoring.
How is the Nipah virus transmitted?
Nipah is a zoonotic virus, meaning It is transmitted from animals to people and, in certain circumstances, between humans.Its main natural reservoirs are the fruit-eating bats of the genus Pteropus, widespread in South and Southeast Asia, as well as in some areas of Africa.
These bats can eliminate the virus through saliva, urine, and feces. Transmission to humans can occur through direct contact with animals or their secretions.through exposure to contaminated food—fruits, palm sap, etc.—or through intermediate hosts such as pigs, which act as amplifiers of the pathogen.
In several outbreaks, the usual form of transmission has been Consumption of juices and foods contaminated by batsespecially date palm sap collected in open bowls overnight. These containers can become filled not only with sap, but also with traces of bat saliva, urine, or feces, which introduce the virus into the human food chain.
Close contact with infected domestic animals, especially pigs, represents another significant route of transmission. Handling sick animals, their tissues, or fluids without protective measures clearly increases the risk. Therefore, Pig farms in high-risk areas must take extra precautions regarding biosecurityprotecting food and corrals from the presence of bats.
It has also been shown person-to-person transmissionespecially in family and healthcare settings. Transmission usually requires close contact with the bodily fluids of infected patients—respiratory secretions, blood, urine—particularly when appropriate protective equipment is not used. However, it does not spread as easily as other respiratory viruses such as influenza or SARS-CoV-2.
Prevention and One Health approach
In the absence of an authorized vaccine and a fully validated specific treatment, preventive measures are our main tool against Nipah. International organizations such as the WHO and the ECDC insist on a One Health approach, which integrates human, animal and environmental health to address these types of threats.
In practice, this translates into Minimize points of contact between bats, domestic animals and peopleIn endemic regions, it is recommended to prevent bats from accessing the date palm sap by using physical coverings, boiling freshly collected sap, carefully washing and peeling the fruit, and discarding any pieces showing signs of bat bites.
In the agricultural and livestock sector, the authorities advise Keep domestic animals—especially pigs—away from trees where bats roost and reinforce hygiene and protection measures for feed and drinking water. In case of suspected infection in animals, the use of gloves, masks, and protective clothing is essential for those who must handle them or participate in selective culling.
In healthcare facilities, the priority is infection prevention and controlThis includes proper risk assessment, isolation of suspected cases, adequate ventilation of rooms, and consistent use of personal protective equipment: masks, goggles, gloves, and gowns. When properly implemented, these measures have proven sufficient to curb transmission chains in previous outbreaks.
At the community level, accurate information and health education play a key role. how the virus is transmitted, what the symptoms are, and what practices should be avoided It allows for the reduction of risky behaviors without generating unjustified fear. In Europe, the main message is one of calm: the virus is being closely monitored, the risk is very low, and existing public health tools are, for now, sufficient.
Treatments and vaccines in development
Day by day, There is no specific antiviral treatment or generally authorized vaccine against NipahMedical care focuses on supportive care: stabilizing the patient, treating respiratory and neurological complications, and providing intensive support when needed. Early intervention can improve the chances of survival.
However, there are several promising lines of research. Among them, the following stand out: monoclonal antibodiesThese are molecules designed to bind very specifically to the virus and inactivate it. One of the most studied is M102.4, which has completed phase 1 clinical trials and has been used compassionately in some specific situations. Another candidate, the human antibody Hu1F5, has shown superior efficacy in non-human primate models and is progressing toward human clinical trials.
The antiviral remdesivir, known for its use during the Covid-19 pandemic, has demonstrated effectiveness against Nipah in non-human primates when administered as post-exposure prophylaxis. Data in animal models support the possibility of human clinical trials combining these monoclonal antibodies and antivirals, although it is still too early to speak of standardized treatments.
In the field of vaccines, various platforms are being explored. One of them is the vaccine based on the ChAdOx1 vectorDeveloped by the University of Oxford and applied to the ChAdOx1 NipahB candidate. In December 2025, the first phase II clinical trial of a Nipah vaccine in humans was launched, a significant milestone in the race to have preventive tools.
Another candidate is the mRNA vaccine mRNA-1215Inspired by the same technology used against the coronavirus, trials in healthy adults between 18 and 60 years old are showing, for now, reasonably positive expectations regarding safety and immunogenicity, although its efficacy will need to be confirmed in subsequent studies. Live attenuated vector vaccines, such as the one based on the vesicular stomatitis virus (PHV02), are also being investigated.
Although these advances indicate that there could be effective solutions in the not-too-distant future, Prevention remains, for the time being, the main barrier against NipahUntil one of these vaccines or treatments conclusively demonstrates its efficacy and safety, the key is to detect cases quickly, isolate them, and minimize exposure to sources of infection.
The emergence of new Nipah virus cases in India illustrates how a little-known pathogen can generate global concern in a matter of days, but it also shows that public health tools, international surveillance, and the One Health approach allow us to keep the risk to Europe at very low levels; closely monitoring the evolution of the outbreak, strengthening cooperation between countries, and applying sensible prevention measures is, for now, the best way to live with this virus without falling into unnecessary alarmism.
